Table 2.
Antiviral results of combinational treatments.
| Combination Ratio (EC50) | EC50 in Combination | EC50 Alone | EC50 Equivalent a | FICI b | |||
|---|---|---|---|---|---|---|---|
| Hesperadin: Oseltamivir | Hesperadin (μM) | Oseltaimivir (nM) | Hesperadin (μM) | Oseltaimivir (nM) | Hesperadin | Oseltaimivir | |
| 10:1 | 0.48 ± 0.15 | 1.1 ± 0.25 | 0.238 | 0.106 | 0.34 | ||
| 5:1 | 0.56 ± 0.05 | 2.26 ± 0.20 | 0.277 | 0.217 | 0.49 | ||
| 1:1 | 0.17 ± 0.20 | 3.44 ± 1.01 | 2.02 ± 0.18 | 10.10 ± 3.11 | 0.084 | 0.331 | 0.41 |
| 1:5 | 0.037 ± 0.006 | 3.73 ± 0.62 | 0.018 | 0.359 | 0.38 | ||
| 1:10 | 0.034 ± 0.052 | 6.28 ± 1.17 | 0.017 | 0.604 | 0.62 | ||
Values are means ± SD (n = 8) from two independent experiments. a Concentration in EC50 equivalent was the normalized concentration that was calculated by dividing the EC50 of drug in combination with its EC50 alone; b FICI was the sum of hesperadin and Oseltamivir EC50-equivalent concentrations used in each combination.